Cerity Partners LLC trimmed its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 24.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,679 shares of the company's stock after selling 15,211 shares during the period. Cerity Partners LLC owned about 0.15% of Medpace worth $15,510,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the company. Proficio Capital Partners LLC raised its stake in shares of Medpace by 34,497.4% in the fourth quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock valued at $80,575,000 after acquiring an additional 241,827 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Medpace during the fourth quarter worth $78,144,000. Norges Bank bought a new position in shares of Medpace in the fourth quarter valued at about $69,859,000. GW&K Investment Management LLC grew its holdings in Medpace by 93.9% during the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock worth $91,516,000 after acquiring an additional 133,379 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its stake in shares of Medpace by 738.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 120,928 shares of the company's stock worth $40,176,000 after acquiring an additional 106,498 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.
Medpace Trading Down 0.7 %
Shares of Medpace stock traded down $2.03 during trading hours on Tuesday, reaching $303.26. 176,211 shares of the company's stock were exchanged, compared to its average volume of 320,014. The company has a 50 day moving average of $322.58 and a two-hundred day moving average of $334.29. The stock has a market cap of $9.17 billion, a P/E ratio of 24.01, a P/E/G ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a fifty-two week low of $272.00 and a fifty-two week high of $459.77.
Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the company. Mizuho lowered their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Truist Financial reduced their price target on Medpace from $347.00 to $333.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Leerink Partnrs upgraded Medpace to a "hold" rating in a report on Monday, March 24th. TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and decreased their target price for the stock from $370.00 to $328.00 in a research report on Monday. Finally, Robert W. Baird upped their price target on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Ten research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $357.50.
View Our Latest Report on Medpace
Medpace Profile
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Further Reading
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
